



In-vitro growth characteristics of commercial probiotic strains and their potential for inhibition of *Clostridium difficile* and *Clostridium perfringens*

Schoster, A.; Permin, A.; Kokotovic, Branko; Dedenroth, P.; Guardabassi, L.

Publication date:
2012

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):

Schoster, A., Permin, A., Kokotovic, B., Dedenroth, P., & Guardabassi, L. (2012). In-vitro growth characteristics of commercial probiotic strains and their potential for inhibition of *Clostridium difficile* and *Clostridium perfringens*. Poster session presented at 2012 ACVIM Forum, New Orleans, LO, United States.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

IN-VITRO GROWTH CHARACTERISTICS OF COMMERCIAL PROBIOTIC STRAINS AND THEIR POTENTIAL FOR INHIBITION OF *CLOSTRIDIUM DIFFICILE* AND *CLOSTRIDIUM PERFRINGENS*

A Schoster¹, B Kokotovic², A Permin³, P Dedenroth⁴, L Guardabassi¹.

¹Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark

²Technical University of Denmark, Copenhagen, Denmark

³The DHI group, Copenhagen, Denmark

⁴Clerici-Sacco Group, Cadorago, Italy

Background

C. difficile and *C. perfringens* are important animal pathogens. There are currently no preventative measures and therapeutics are limited to antibiotics. With antibiotic resistance on the rise new approaches are needed.

Probiotics have been evaluated in humans in relation to clostridial disease and results have been promising. There are no animal probiotics licensed for use against clostridial disease.

Many strains that show promising activity can not be commercially produced as they are not technically robust. This could be overcome by using strains already in commercial production.

Objective and Hypothesis


1) To assess the ability of selected commercial probiotic strains to inhibit growth of *C. difficile* and/or *C. perfringens* in vitro

2) To evaluate their ability to grow in the presence of oxygen, acid and bile

Strain	Trade Name	MRS	pH 4	pH 2	Bile 0.3%	Bile 0.15%
<i>L. plantarum</i>	BG112	100	81	1	85	95
<i>L. rhamnosus</i>	LRH19	100	40	0	63	83
<i>L. plantarum</i>	LPAL	100	60	1	90	99
<i>L. rhamnosus</i>	SP1	100	75	0	71	81
<i>B. animalis spp lactis</i>	BLC1	100	77	0	92	96

Table 2 Growth characteristics of 5 selected probiotic strains with inhibitory activity against clostridia in standard Man-Rogosa-Sharpe (MRS) broth, MRS broth adjusted to pH2.0 and pH4.0, and MRS broth with 0.3% or 0.15% bile added. The numbers are given as percentage of growth compared to growth in normal MRS broth

Figure 1 Inhibition of *C. perfringens* by cell-free supernatants at pH_{orig} and pH_{adj}, obtained from *B. animalis lactis* BLC1 and unsuccessful inhibition by *L. plantarum* LBd. 12h, 24h, 36h, 48h: Probiotic supernatant obtained after respective incubation time. Center well: Sterile MRS broth adjusted to pH3.9 or standard MRS broth (pH_{orig})



Material and Methods

Seventeen probiotic strains were used (Table 1).

Inhibition of *C. difficile* and *C. perfringens*

The effect of a cell free probiotic culture supernatant on the growth of *C. difficile* ribotype 078 and *C. perfringens* Type C was assessed. Supernatant was harvested and sterilized after 12, 24, 36, 48, and 72 hours and six days. One aliquot was adjusted to pH7.4 (pH_{adj}) the other aliquot was left at original pH (pH_{orig}).

Agar well diffusion assay

The anti-clostridial activity was evaluated by agar well diffusion following addition of supernatant at pH_{orig} or pH_{adj}.

Broth co-culture in Brain Heart Infusion (BHI)

BHI broth was inoculated with *C. difficile* or *C. perfringens* and probiotic supernatant (t48h, pH_{orig} or pH_{adj}). Clostridial growth was compared to growth of a control culture with Man-Rogosa-Sharpe (MRS) at pH7.0 or pH3.9 instead of supernatant using spectrophotometry. Inhibition was indicated by a reduction of growth of at least 50%.

Evaluation of growth characteristics

Aerobic and anaerobic growth of probiotics was assessed visually. Growth was compared between growth in standard MRS broth, MRS pH2.0 and pH4.0, and MRS supplemented with 0.15% and 0.3% bile spectrophotometrically.

Results

Inhibition of *C. difficile* and *C. perfringens*

Agar well diffusion assay (Fig. 1)

- 2/17 strains inhibited *C. perfringens* (Tab. 1)
 - Supernatant from all timepoints (growth phases) was inhibitory
 - Supernatant at pH_{orig} and pH_{adj} was inhibitory
 - Inhibition of pH_{orig} was greater indicating presence of an additional antibiotic compound other than organic acids
- 10/ 12 strains inhibited *C. difficile* (Tab. 1)
 - Only supernatant with pH_{orig} was inhibitory indicating inhibition due to organic acids
 - Only supernatant harvested after at least 36h of incubation inhibited *C. difficile*.

Broth co-culture

- 5/17 probiotics inhibited *C. perfringens* and 10/17 inhibited *C. difficile* (Tab. 1)
- Inhibition was only seen with supernatant at pH_{orig}

Growth characteristics

- All strains grew aerobically except *B. animalis lactis*.
- None of the strains grew at pH2, growth at pH4 ranged between 40-95%
- Growth ranged from 40-99% when bile was added
- Growth parameters of selected probiotic strains that showed inhibitory potential against both clostridia are presented in Table 2.

Strain	Trade Name	<i>C. difficile</i>		<i>C. perfringens</i>	
		Agar Well	Broth	Agar Well	Broth
<i>L. plantarum</i>	BG112	✓	✓	x	✓
<i>E. faecium</i>	EF1	x	x	x	x
<i>L. casei</i>	LC11	✓	✓	x	x
<i>L. rhamnosus</i>	LRH19	✓	✓	x	✓
<i>L. fermentum</i>	Lba	x	x	x	x
<i>L. helveticus</i>	LH62	x	x	x	x
<i>L. brevis</i>	LBR9	x	x	x	x
<i>L. salivarius</i>	LBb	✓	x	x	x
<i>L. plantarum</i>	LBc	✓	✓	x	x
<i>L. plantarum</i>	LPAL	✓	✓	✓	✓
<i>L. plantarum</i>	LBd	✓	✓	x	x
<i>L. casei</i>	LC10	x	✓	x	x
<i>L. sakei</i>	LS-B	x	x	x	x
<i>L. rhamnosus</i>	LRB	✓	✓	x	x
<i>E. faecium</i>	SF02	x	x	x	x
<i>L. rhamnosus</i>	SP1	✓	✓	x	✓
<i>B. animalis spp lactis</i>	BLC1	✓	✓	✓	✓

Table 1 Inhibitory activity of probiotic supernatant against *C. perfringens* and *C. difficile* in agar well diffusion and broth co-culture assays. Probiotics outlined in yellow and blue showed inhibition against both clostridia. Probiotics outlined in blue showed inhibition against both clostridia in both assays. Fields outlined in green show inhibitory potential in the respective experiment against the respective clostridial strain.

Conclusions

- 5 strains (*L. plantarum* (n=2), *L. rhamnosus* (n=2) and *B. animalis lactis*) inhibit clostridial growth by a reduction of pH. This inhibitory effect is likely due to organic acid production during stationary growth phase
- 2 of the 5 strains (*L. plantarum*, *B. animalis*) produce an additional antibiotic compound that inhibits *C. perfringens* only. This compound is produced during the exponential phase and it's activity is pH-independent.
- These 5 strains show growth characteristics suitable for probiotics and their possible use for control of clostridial disease will be further explored by in-vitro and in-vivo studies.

Contact Information

Angelika Schoster
E-mail: aschoster@life.ku.dk
University of Copenhagen
Department of Veterinary Disease Biology
Faculty of Health and Medical Sciences